MX359337B - Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer. - Google Patents

Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.

Info

Publication number
MX359337B
MX359337B MX2015012063A MX2015012063A MX359337B MX 359337 B MX359337 B MX 359337B MX 2015012063 A MX2015012063 A MX 2015012063A MX 2015012063 A MX2015012063 A MX 2015012063A MX 359337 B MX359337 B MX 359337B
Authority
MX
Mexico
Prior art keywords
cancer
oligonucletotides
antisense
treatment
stem cells
Prior art date
Application number
MX2015012063A
Other languages
English (en)
Other versions
MX2015012063A (es
Inventor
A Burzio Menendez Veronica
E Villegas Olavarria Jaime
O Burzio Eriz Luis
Original Assignee
Andes Biotechnologies Global Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andes Biotechnologies Global Inc filed Critical Andes Biotechnologies Global Inc
Publication of MX2015012063A publication Critical patent/MX2015012063A/es
Publication of MX359337B publication Critical patent/MX359337B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un compuesto para usarse en un método para tratar o suprimir la metástasis de un cáncer en un individuo, donde el compuesto comprende una cantidad efectiva de uno o más oligonucleótidos complementarios a una molécula de ARN mitocondrial quimérico no codificante humano que comprende: a. un ARN ribosómico mitocondrial 16S antisentido enlazado covalentemente en su extremo 5´al extremo 3´de un polinucleótido con una secuencia repetida invertida, o b. un ARN ribosómico mitocondrial 16S sentido enlazado covalentemente en un extremo 5´ al extremo 3´de un polinucleótido con una secuencia repetida invertida, en donde el uno o más oligonucleótidos son capaces de hibridizar con las moléculas de ARN mitocondrial quimérico para formar un dúplex estable, y en donde el individuo previamente ha sido tratado para cáncer con una terapia.
MX2015012063A 2013-03-14 2014-03-14 Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer. MX359337B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361785269P 2013-03-14 2013-03-14
US201361790072P 2013-03-15 2013-03-15
US201461937438P 2014-02-07 2014-02-07
PCT/US2014/029606 WO2014153209A1 (en) 2013-03-14 2014-03-14 Antisense oligonucletotides for treatment of cancer stem cells

Publications (2)

Publication Number Publication Date
MX2015012063A MX2015012063A (es) 2016-04-06
MX359337B true MX359337B (es) 2018-07-09

Family

ID=51581450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012063A MX359337B (es) 2013-03-14 2014-03-14 Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.

Country Status (14)

Country Link
US (3) US9862944B2 (es)
EP (1) EP2970970B1 (es)
JP (1) JP6313419B2 (es)
CN (2) CN105229150A (es)
BR (1) BR112015022308A8 (es)
CA (1) CA2906198C (es)
CL (1) CL2015002612A1 (es)
DK (1) DK2970970T3 (es)
ES (1) ES2708650T3 (es)
HK (1) HK1220482A1 (es)
HU (1) HUE042738T2 (es)
MX (1) MX359337B (es)
PL (1) PL2970970T3 (es)
WO (1) WO2014153209A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105283466A (zh) 2013-03-14 2016-01-27 安第斯生物技术股份有限公司 用于检测和治疗多发性骨髓瘤的方法
WO2014153209A1 (en) 2013-03-14 2014-09-25 Andes Biotechnologies S.A. Antisense oligonucletotides for treatment of cancer stem cells
KR102145176B1 (ko) * 2017-11-27 2020-08-18 (주)프로스테믹스 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
AU2019440405A1 (en) * 2019-04-11 2021-12-09 Genex Health Co., Ltd Method for culturing primary cells of gastric cancer and gallbladder and bile duct cancer, and supporting reagents
CN113893261B (zh) * 2021-06-22 2023-01-13 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） circITGB6-ASO与铂类化疗药物联合使用在制备治疗卵巢癌的药物中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
ATE113059T1 (de) 1987-06-24 1994-11-15 Florey Howard Inst Nukleosid-derivate.
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5721218A (en) 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5614617A (en) 1990-07-27 1997-03-25 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
HU217036B (hu) 1990-08-03 1999-11-29 Sanofi Eljárás génexpresszió gátlására alkalmas vegyületek előállítására
EP0549686A4 (en) 1990-09-20 1995-01-18 Gilead Sciences Inc Modified internucleoside linkages
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
CA2159629A1 (en) 1993-03-31 1994-10-13 Sanofi Oligonucleotides with amide linkages replacing phosphodiester linkages
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5646269A (en) 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US8715645B2 (en) 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
DK1003850T3 (da) 1997-06-06 2009-09-07 Univ California Inhibitorer af DNA-immunstimulatorisk sekvensaktivitet
EP2270159B1 (en) 2003-05-21 2015-01-07 Andes Biotechnologies S.A. Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein
EP1938906B1 (en) 2005-10-20 2016-12-07 Tokuyama Corporation Method for removing mixed air in coating liquid
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
WO2007143317A2 (en) 2006-05-05 2007-12-13 Isis Pharmaceuticals, Inc Compounds and methods for modulating expression of crp
WO2009026576A1 (en) 2007-08-23 2009-02-26 Keren Pharmaceuticals Targeting rna with external guide sequences
MX2010005594A (es) 2007-11-20 2010-08-31 Hopitaux Universitaires De Gen Metodos para identificar, purificar y enriquecer celulas madre o inmaduras que inician el cancer a partir de tumores y uso de las mismas.
US8431544B1 (en) * 2009-08-27 2013-04-30 Idera Pharmaceuticals, Inc. Compositions for inhibiting gene expression and uses thereof
WO2014153209A1 (en) 2013-03-14 2014-09-25 Andes Biotechnologies S.A. Antisense oligonucletotides for treatment of cancer stem cells
CN105283466A (zh) 2013-03-14 2016-01-27 安第斯生物技术股份有限公司 用于检测和治疗多发性骨髓瘤的方法

Also Published As

Publication number Publication date
US20200239885A1 (en) 2020-07-30
PL2970970T3 (pl) 2019-06-28
BR112015022308A8 (pt) 2018-01-23
BR112015022308A2 (pt) 2017-10-10
HUE042738T2 (hu) 2019-07-29
US9862944B2 (en) 2018-01-09
EP2970970A4 (en) 2016-10-19
EP2970970A1 (en) 2016-01-20
CL2015002612A1 (es) 2016-08-26
WO2014153209A8 (en) 2015-02-26
WO2014153209A1 (en) 2014-09-25
HK1220482A1 (zh) 2017-05-05
DK2970970T3 (en) 2019-02-11
US20160138015A1 (en) 2016-05-19
CA2906198C (en) 2022-11-29
US10457943B2 (en) 2019-10-29
ES2708650T3 (es) 2019-04-10
US11319535B2 (en) 2022-05-03
JP6313419B2 (ja) 2018-04-18
EP2970970B1 (en) 2018-12-12
CN115518073A (zh) 2022-12-27
US20180171335A1 (en) 2018-06-21
CA2906198A1 (en) 2014-09-25
MX2015012063A (es) 2016-04-06
CN105229150A (zh) 2016-01-06
JP2016519084A (ja) 2016-06-30

Similar Documents

Publication Publication Date Title
MX2018012880A (es) Metodos para proporcionar arn de hebra sencilla.
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2015008697A (es) Tratamiento contra la degeneración macular relacionada con la edad.
WO2016106400A3 (en) Rna interference agents for gst-pi gene modulation
MX2016004678A (es) Composiciones para el tratamiento del cancer.
PH12018502569A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2015015564A (es) Moduladores de oligonucleotido de linfoma linfocitico cronico/linfoma de celulas b 11a (bcl11a) y sus usos.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX359337B (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
PH12015501038A1 (en) Inhibitors of iap
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
GB2507700A (en) Compositions and methods for treatment of metastatic cancer
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
PH12014502109A1 (en) Methods of treating cancer using aurora kinase inhibitors
NZ744845A (en) Cancer treatment
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
PH12018502571A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
EA201992441A1 (ru) Способы лечения с использованием аденовируса
UA70225U (ru) Применение композиции, содержащей мирамистин, в качестве лекарственного средства для лечения заболеваний горла

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ANDES BIOTECHNOLOGIES GLOBAL, INC.

HC Change of company name or juridical status

Owner name: ARRIS ENTERPRISES, LLC

FG Grant or registration